DOCSLIB.ORG

View U.S. Patent No. 10434110 in PDF Format

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
View U.S. Patent No. 10434110 in PDF Format I 1111111111111111 1111111111 111111111111111 IIIII IIIII 11111 111111111111111111 US010434110B2 c12) United States Patent (IO) Patent No.: US 10,434,110 B2 DeLuca et al. (45) Date of Patent: Oct. 8, 2019 (54) USE OF HOMOSALATE AND OCTYL Agranoff BW & Goldberg D (1974) Diet and the geographical SALICYLATE TO TREAT MULTIPLE distribution of multiple sclerosis. Lancet (London, England) SCLEROSIS 2(7888): 1061-1066. Becklund BR, Severson KS, Vang SV, & DeLuca HF (2010) UV (71) Applicant: Wisconsin Alumni Research radiation suppresses experimental autoimmune encephalomyelitis Foundation, Madison, WI (US) independent of vitamin D production. Proceedings of the National Academy of Sciences of the United States of America 107(14):6418- (72) Inventors: Hector F. DeLuca, Deerfield, WI (US); 6423. Steven Marling, Madison, WI (US); Compston A & Coles A (2002) Multiple sclerosis. Lancet (London, Lori A. Plum, Arena, WI (US); England) 359(9313):1221-1231. Yanping F. Wang, Madison, WI (US) Couteau C, Chauvet C, Paparis E, & Coiffard L (2012) UV filters, ingredients with a recognized anti-inflammatory effect. PloS one (73) Assignee: WISCONSIN ALUMNI RESEARCH 7(12):e46187. FOUNDATION, Madison, WI (US) Farah AE & Rosenberg F (1980) Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors. British journal of ( *) Notice: Subject to any disclaimer, the term ofthis clinical pharmacology 10 Suppl 2:26ls-278s. Goldberg P (1974) Multiple sclerosis: vitamin D and calcium as patent is extended or adjusted under 35 environmental determinants of prevalence. International Journal of U.S.C. 154(b) by O days. Environmental Studies 6(1):19-27. MacLaughlin JA, Anderson RR, & Holick MF (1982) Spectral (21) Appl. No.: 15/643,988 character of sunlight modulates photosynthesis of previtamin D3 and its photoisomers in human skin. Science (New York, N.Y.) (22) Filed: Jul. 7, 2017 216(4549): 1001-1003. Marusic S, et al. (2008) Blockade of cytosolic phospholipase A2 (65) Prior Publication Data alpha prevents experimental autoimmune encephalomyelitis and US 2018/0015107 Al Jan. 18, 2018 diminishes development of Thl and Thl 7 responses. Journal of neuroimmunology 204 (1-2):29-37. Related U.S. Application Data Miller H, Newell DJ, & Ridley A (1961) Multiple sclerosis. Trials of maintenance treatment with prednisolone and soluble aspirin. (60) Provisional application No. 62/362,951, filed on Jul. Lancet (London, England) 1(7169):127-129. 15, 2016. Miyamoto K, et al. (2006) Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX- (51) Int. Cl. 2-independent pathway. Brain a journal of neurology 129(Pt A61K 311618 (2006.01) 8):1984-1992. A61K 8137 (2006.01) Modi, Khushbu K et al., "Up-regulation of Ciliary Neurotrophic A61K 9/00 (2006.01) Factor in Astrocytes by Aspirin: Implications for Remyelination in A61Q 17104 (2006.01) Multiple Sclerosis," Journal of Biological Chemistry, vol. 288, No. A61K 31/60 (2006.01) 25, May 7, 2013, pp. 18533-18545. (52) U.S. Cl. Paulus HE & Whitehouse MW (1973) Nonsteroid anti­ CPC A61K 311618 (2013.01); A61K 8137 inflammatory agents. Annual review of pharmacology 13: 107-125. (2013.01); A61K 9/0014 (2013.01); A61K Rose JW, Hill KE, Watt HE, & Carlson NG (2004) Inflammatory 9/0019 (2013.01); A61K 9/0053 (2013.01); cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. A61K 31/60 (2013.01); A61Q 17104 (2013.01); Journal of neuroimmunology 149(1-2):40-49. A61K 2800/91 (2013.01); A61K 2800/92 Tsau S, Emerson MR, Lynch SG, & LeVine SM (2015) Aspirin and (2013.01) multiple sclerosis. BMC medicine 13:153. Wang Y, et al. (2013) Suppression of experimental autoimmune ( 58) Field of Classification Search encephalomyelitis by 300-315nm ultraviolet light. Archives of None biochemistry and biophysics 536(1):81-86. See application file for complete search history. Wang Y, Marling SJ, Martino VM, Prahl JM, & Deluca HF (2016) The absence of 25-hydroxyvitamin D3-lalpha-hydroxylase poten­ (56) References Cited tiates the suppression of EAE in mice by ultraviolet light. The Journal of steroid biochemistry and molecular biology. FOREIGN PATENT DOCUMENTS * cited by examiner WO W02010/076731 * 7/2000 ......... A61K 31/4184 OTHER PUBLICATIONS Primary Examiner - Jake M Vu (74) Attorney, Agent, or Firm -Quarles & Brady LLP Orton et al (Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology. Feb. 1, 2011; 76(5): 425-431).* (57) ABSTRACT Koriem et al (Multiple sclerosis: New insights and trends. Asian Pacific Journal of Tropical Biomedicine. vol. 6, Issue 5, May 2016, A method of treating an MS patient with homosalate, octyl pp. 429-440).* salicylate, or a combination is disclosed. International Search Report and Written Opinion issued in corre­ sponding International Application No.PCT/US2017 /041092, dated Aug. 30, 2017, 7 pages. 10 Claims, 12 Drawing Sheets U.S. Patent Oct. 8, 2019 Sheet 1 of 12 US 10,434,110 B2 1 3 5 7 9 11 13 15 17 19 21 23 25 27 Sunscreen Days Post Immunization Fig. 1 U.S. Patent Oct. 8, 2019 Sheet 2 of 12 US 10,434,110 B2 The Effect of Sunscreen Ingredients on EAE - Test 1 3.5 ~ Control ~ 8 3.0 VI ~ 2.5 "0 •.•.•.•-:=,•-•.•.• Dxybenzone .E 2.0 QI •.•.•·''·"-····· Avobenzone ~ 1.5 QI ~oxy+Avo i5 1.0 g:, 0.5 ~Sunscreen ~ l o.o .:.. s::,, s:: s:: s:: s:: s:: $;!' """. -~, ..... , ........ 1 3 5 7 9 11 13 15 17 19 21 23 25 27 ·-29 Days Post Immunization Fig. 2A 24.0 23.0 22.0 ~Control :§ 21.0 -~DMSO 3 20.0 ......,,,,, ....... Oxybenzone > -a ~ 19.0 ......., .. ,....... Avobenzone 18.0 - Oxy + Avo 17.0 ~Sunscreen 16.0 1 2 3 4 5 Weeks Post Immunization Fig. 2B U.S. Patent Oct. 8, 2019 Sheet 3 of 12 US 10,434,110 B2 The Effect of Sunscreen Ingredients on EAE - Test w~ -N~~w 2 6 Control ..... A ,X 3. 0 .. :❖• ••. ···,~•.,.•• .-·. .,,•• , .••••• ra ····•·:~~--·.·· Homosalate s~·····-·-=-:<"•. ...... •.·•-::~......... :~.......... ::.•-•.•·-... ❖-•··•·..:..::-·'"•.•·· --❖-----.°'::-....... :y. j2D ;· uc: 1 O ·1 .......,,;;:.•.•.• octyl .... ······ ;.<' •.. •.. ,:::- •..•..::,·······'"''······•·-:: •••.•.• ,,,;:"······='=····••.,,,,. ' . ... :::::·•··• .•.• .v·••:❖:•••:•:❖•-·•:::::•··•·::;.:-·•···•;::(" ~ o:o l::::: ....... s:ic~at~ *. *. * ·L·:-t··:·:::·:::i ~-· & . % . «:.:::::. ;_~ .·:::::·. 'k:W· ~:·w·:w -w. ·:·::: ..¾ .•~~.<-Homo 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 Days Post Immunization Fig. 3A Weights 25.0 24.0 23.0 ::§ 22.0 ...... +•-•.•. Negative Control 3 21.0 ......;:;:;.-.-.-. Homosa late ~ 20.0 ......,,,,, ....... octyl salicylate ~ 19.0 18.0 ·••·"····· Homo + Octi 17.0 ~sunscreen 16.0 1 2 2 4 5 Weeks Post Immunization Fig. 3B U.S. Patent Oct. 8, 2019 Sheet 4 of 12 US 10,434,110 B2 Fig. 4A 4.5 ! ■ Control 4 .0 !~NBUVB 3.5 i ~ SS+NBUVB ~ 3.0 0 65 2.5 ~ 2.0 <I) :;§: 1.5 1 0 · . TT TT TT L 0. 5 +❖~---w·1.JlL1 · · +.-0-,tA::A=' Q-¼;l,~~;¾nfl,#~h◊,~~/4-t<w&Y'{k:".!fy.:$-t%,<~~~-,¢y;~-0-,-$:-, 1 3 7 9 11 13 15 17 19 21 23 25 27 29 Days Post-Immunization Fig. 4B 25 20 5 ■ Control ❖ NBUVB *SS+NBUVB o+====;:::::::..-----,-----.----....-------.. 2 :3 4 5 Weeks Post-Immunization Fig. 4C 4.5 ■ Control 4 .0 4NBUVB 3.5 ~ss .§ SS+NBUVB ~ 3.0 0 bJ 2.5 ~ 2.0 <O ~ 1.5 1.0 0.5 0-l-®,%,<®-&:-;-%-,~~~M~~~-fi.:>.r~~r$.,-1:Nil~~~/4M~ 3 5 7 9 11 13 15 17 19 21 23 25 27 Days Post-Immunization U.S. Patent Oct. 8, 2019 Sheet 5 of 12 US 10,434,110 B2 3.5 Fig. 5A ■ Control 3.0 .& CotZ Face l· Banana Boat Kids 2.5 ~ Blue Lizard ~ 0 ,,,,, Kiss My Face !,) 2.0 (f) Y Coppertone (Spray) c ~ Hawaiian Tropic ~ i.5 ~ 1.0 0.5 O+M~~~;UU;~.,..,~~~~~~~ 3 5 7 9 11 13 15 17 19 21 23 25 27 29 Days Post-Immunization 3.5 Fig. 5B 3.0 2.5 ~ 0 u 2.0 (f) C ~ 1.5 ~ ■ Control 1.0 .& Darkness from -7 to 30 -,} Darkness from Oto 30 0.5 '? Darkness from 10 to 30 ~ Darkness from 20 to 30 3 5 7 9 11 13 15 17 19 21 23 25 27 29 Days Post-Immunization U.S. Patent Oct. 8, 2019 Sheet 6 of 12 US 10,434,110 B2 Fig. 6A Fig. 6B 4 30 ■ Control <I> Pretreatment 25 Immunization 3 ♦ x Onset § 20 :E ·a;"" 15 s °8 10 co 5 0 0+-------~----------~ 1 3 5 7 9 11 13 15 17 ·19 21 23 25 27 29 2 3 4 5 Days Post-Immunization Weeks Post¥lmmw1ization 4 .. 25 ■ Contrcl .,.ss 25 µL 50 µL 20 3 "'SS ♦ SS 100 µL § ~ t 15 (/J'·' 2 C. ~ .,"' ;;,, 10 2 '8 co 5 0 0+-------~----------~ 3 5 7 9 11 13 15 17 19 21 23 25 27 29 2 3 4 5 Days Po~t-lmmunization W..eks Post-Immunization Fig. 6C Fig. 6D U.S. Patent Oct. 8, 2019 Sheet 7 of 12 US 10,434,110 B2 Fig. 7A Fig. 7B 3.5 24 ■ Control ·····•: 3.0 ❖-DMSO ._ Ox)'ban2one 2.5 ,,,. Avobenzon e § 22 >); .-ii>-~-'&/;:::~;~1 6 ~ Oxy +Avo w 2.0 ~Sun-screen ff) £i ~ 20 .,,~ 1.5 2 t' 1.0 s 18 0.€, 0 ·&:("%y.$y:::!)'&·;·%'c (:::,1'::::"i-:;::i::$:,-::;-f:::-)'-»j•»("%f::•,-:-::-,.~~i•%'(%"f:::-{-::-i*-:~·(::;p,-, 16+-----,------,-----r-----,------, 3 5 7 9 11 r13 15 17 19 21 23 25 27 29 2 3 4 5 Days Post-Immunization \.,..,~leeks Post~ Immunization 3.5 24 ■ Control 3.0 -. Homosalate "Octisalate 22 2.5 -t>Homo+Octi :§ ~ •::: Sunscreen Spray! 0 :E w 2.0 OJ w ·;;; 20 C. 5 "'.,, 1.5 2 1.0 t Cll 18 0.5 0 :.:::y:::-<::::,:.::f'.::~1::::yZ.j:::.:c:::;:,.:~·-·/i:yt:l:•f:~:•1:~;..,;:;::{:::,.:::•1:~;--i=::~~%1 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 2 3 4 5 Days Post-Immunization Weeks Post-Immunization Fig.
Load more

Recommended publications
  • FDA Proposes Sunscreen Regulation Changes February 2019
    FDA Proposes Sunscreen Regulation Changes February 2019 The U.S. Food and Drug Administration (FDA) regulates sunscreens to ensure they meet safety and eectiveness standards. To improve the quality, safety, and eectiveness of sunscreens, FDA issued a proposed rule that describes updated proposed requirements for sunscreens. Given the recognized public health benets of sunscreen use, Americans should continue to use broad spectrum sunscreen with SPF 15 or higher with other sun protective measures as this important rulemaking eort moves forward. Highlights of FDA’s Proposals Sunscreen active ingredient safety and eectiveness Two ingredients (zinc oxide and titanium dioxide) are proposed to be safe and eective for sunscreen use and two (aminobenzoic acid (PABA) and trolamine salicylate) are 1 proposed as not safe and eective for sunscreen use. FDA proposes that it needs more safety information for the remaining 12 sunscreen ingredients (cinoxate, dioxybenzone, ensulizole, homosalate, meradimate, octinoxate, octisalate, octocrylene, padimate O, sulisobenzone, oxybenzone, avobenzone). New proposed sun protection factor Sunscreen dosage forms (SPF) and broad spectrum Sunscreen sprays, oils, lotions, creams, gels, butters, pastes, ointments, and sticks are requirements 2 proposed as safe and eective. FDA 3 • Raise the maximum proposed labeled SPF proposes that it needs more data for from SPF 50+ to SPF 60+ sunscreen powders. • Require any sunscreen SPF 15 or higher to be broad spectrum • Require for all broad spectrum products SPF 15 and above, as SPF increases, broad spectrum protection increases New proposed label requirements • Include alphabetical listing of active ingredients on the front panel • Require sunscreens with SPF below 15 to include “See Skin Cancer/Skin Aging alert” on the front panel 4 • Require font and placement changes to ensure SPF, broad spectrum, and water resistance statements stand out Sunscreen-insect repellent combination 5 products proposed not safe and eective www.fda.gov.
    [Show full text]
  • Kroger Co Disclaimer: Most OTC Drugs Are Not Reviewed and Approved by FDA, However They May Be Marketed If They Comply with Applicable Regulations and Policies
    SUNSCREEN- avobenzone, homosalate, octisalate, octocrylene, oxybenzone lotion The Kroger Co Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies. ---------- Kroger 711 Active Ingredients Avobenzone 3% Homosalate 13% Octisalate 5% Octocrylene 7% Oxybenzone 4% Purpose Sunscreen Use helps prevent sunburn if used as directed with other sun protections measures (see Directions), decreases the rist of skin cancer and early skin aging caused by the sun Warnings For external use only Do not use on damaged or broken skin When using this product keep out of eyes. Rinse with water to remove Stop use and ask a doctor if rash occurs Keep out of reach of children if swallowed, get medical help or contact a Poison Control Center right away Directions apply liberally 15 minutes before sun exposure reapply: after 80 minutes of swimming or sweating immediately after towel drying at least every 2 hours ​Sun Protection Measures. ​Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk use a reqularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including: limit time in the sun, especially from 10 a.m. - 2 p.m. wear long-sleeved shirts, pants, hats and sunglasses children under 6 months of age: Ask a doctor Other Information Protect the product from excessive heat and direct sun Inactive ingredients water, sorbitol, triethanolamine, VP/eicosene copolymer, stearic acid, sorbitan isostearate, aluminum starch octenylsuccinate, benzyl alcohol, dimethicone, tocopheryl, chlorphenesin, polyglyceryl-3 distearate, fragrance, carbomer, disodium EDTA Questions or comments? 1-800-632-6900 Adverse Reaction DISTRIBUTED BY THE KROGER CO.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,086,858 Mceleney Et Al
    US006086858A United States Patent (19) 11 Patent Number: 6,086,858 McEleney et al. (45) Date of Patent: *Jul. 11, 2000 54). COLORED FORMULATIONS FOR 4,818,491 4/1989 Fariss. APPLICATION TO HUMAN SKIN 4.954,544 9/1990 Chandaria. 5,426.210 6/1995 Kato et al.. 75 Inventors: John McEleney, Newton; Wende SS 8.1. R el, Restry BMS Curtis A. Vock, 5,562,8962- - -2 10/1996 Repperepper et al..al. s 5,567,420 10/1996 McEleney et al. ....................... 424/60 5,609,852 3/1997 Galley et al.. 73 Assignee: IPA, LLC, Forth Worth, Tex. 5,753,210 5/1998 McEleney et al. ....................... 424/59 c: 5,955,062 9/1999 McEleney et al. ... ... 424/59 * Notice: This patent is Subject to a terminal dis- 5,958,383 9/1999 McEleney et al. ....................... 424/59 CC. OTHER PUBLICATIONS 21 Appl. No.: 09/333,088 Deposition Transcript of Jack Katz, Feb. 10, 1999, pp. 1-32, 22 Filled: 15, 1999 regarding civil action entitled, Playtex Products, Inc. and 22 File Jun. 15, Sun Pharmaceuticals Corporation vs. Schering-Plough Related U.S. Application Data Healthcare Products, Inc., Case No. 98–482-RPM, United States District Court, Middle District of Delaware. 63 Continuation of application No. 09/217,170, Dec. 21, 1998, First Amended Complaint, IPA v Schering-Plough et al., which is a continuation of application No. 09/024,458, Feb. Civil Action No. 98–482 (RRM), Jan. 22, 1999, 14 pages. ship, alengageplain E. Defendants' Answer & Counterclaims to First Amended ation of application N. Soss 64.
    [Show full text]
  • Salicylate UV-Filters in Sunscreen Formulations Compromise the Preservative System Efficacy Against Pseudomonas Aeruginosa and Burkholderia Cepacia
    cosmetics Article Salicylate UV-Filters in Sunscreen Formulations Compromise the Preservative System Efficacy against Pseudomonas aeruginosa and Burkholderia cepacia Noa Ziklo, Inbal Tzafrir, Regina Shulkin and Paul Salama * Innovation department, Sharon Laboratories Ltd., Odem St. Industrial zone Ad-Halom, Ashdod 7898800, Israel; [email protected] (N.Z.); [email protected] (I.T.); [email protected] (R.S.) * Correspondence: [email protected]; Tel.: +972-54-2166476 Received: 15 July 2020; Accepted: 1 August 2020; Published: 3 August 2020 Abstract: Contamination of personal-care products are a serious health concern and therefore, preservative solutions are necessary for the costumers’ safety. High sun protection factor (SPF) sunscreen formulations are known to be difficult to preserve, due to their high ratio of organic phase containing the UV-filters. Salicylate esters such as octyl salicylate (OS) and homosalate (HS) are among the most common UV-filters currently used in the market, and can undergo hydrolysis by esterase molecules produced by contaminant microorganisms. The hydrolysis product, salicylic acid (SA) can be assimilated by certain bacteria that contain the chorismate pathway, in which its final product is pyochelin, an iron-chelating siderophore. Here, we show that OS and HS can compromise the preservative efficacy against two pathogenic important bacteria, Pseudomonas aeruginosa and Burkholderia cepacia. Challenge tests of formulations containing the UV-filters demonstrated that only bacteria with the chorismate pathway failed to be eradicated by the preservation system. mRNA expression levels of the bacterial pchD gene, which metabolizes SA to produce pyochelin, indicate a significant increase that was in correlation with increasing concentrations of both OS and HS.
    [Show full text]
  • EWG Petitions CDC to Conduct Biomonitoring Studies for Common Sunscreen Chemicals
    EWG Petitions CDC To Conduct Biomonitoring Studies for Common Sunscreen Chemicals May 22, 2019 To: U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for Environmental Health Agency for Toxic Substances and Disease Registry 4770 Buford Hwy, NE Atlanta, GA 30341 Patrick Breysse, Ph.D., CIH Environmental Working Group (EWG), a nonprofit research and advocacy organization with headquarters in Washington, D.C., is petitioning the Centers for Disease Control and Prevention to add common sunscreen chemicals to the CDC’s Biomonitoring Program. EWG has been doing research on sunscreen ingredients since 2007, helping to educate the public about the importance of using sunscreens for health protection, as well as providing information about health risks that may be associated with certain ingredients used in sunscreen products. In response to a significant increase in the use of sunscreens in the United States and the associated increased potential for systemic exposure to the ingredients in these products, in February 2019, the Food and Drug Administration proposed a new rule for sunscreen products.1 The proposed rule would require sunscreen active ingredients to be assessed for their propensity to absorb through the skin and overall safety. Recently, the FDA completed tests on the absorbance of four common sunscreen active ingredients: avobenzone, oxybenzone, octocrylene, and ecamsule. As reported in a study published by the Journal of American Medical Association in May 2019,2 application of all four tested sunscreen ingredients resulted in plasma concentrations that exceeded the 0.5 ng/mL threshold proposed by the FDA for waiving systemic carcinogenicity studies as well as developmental and reproductive toxicity studies.
    [Show full text]
  • Sun Protection
    [ Oncology Watch] Sun Protection: What We and Our Patients Need to Know To preserve their health and the appearance of their skin, patients need straight- forward, practical advice on susncreen selection and protection strategies. By Jonathan Wolfe, MD rom preventing skin cancer to pre- measures protection against cutaneous burning. Even a FDA public education serving a youthful appearance, burning—the effects of UVB—and does piece states, “A higher number means it Fsunscreens play an important role not account for UVA radiation at all.5 As protects longer.”7 This is not a strictly in dermatologic care. However, some a result, a product with a high SPF could accurate interpretation of the SPF value confusion persists among patients and actually confer little or no protection and ignores the fact that unique proper- even some practitioners when it comes to against UVA. ties of the main sunscreen ingredients SPF, available chemical and physical sun- The somewhat esoteric description of (chemical or physical) and the formula- screens, and the best advice for sun SPF calculation is available online at the tion (waterproof, water resistant) influ- avoidance. In recognition of the AAD’s FDA website.6 Ultimately, the SPF num- ence duration of protection. Skin Cancer Detection and Prevention ber represents the ratio of the MED for Patients also often falsely assume that Month, I’ll review important patient protected skin (MED(PS)) to the MED the increase in SPF value is proportion- education points. for unprotected skin (MED(US)). Tests ate to the increase in UVB protection. It are conducted only in patients with skin is not.
    [Show full text]
  • Determination of Sun Protection Factor (SPF) of Sunscreens by Ultraviolet Spectrophotometry
    Revista Brasileira de Ciências Farmacêuticas Brazilian Journal of Pharmaceutical Sciences vol. 40, n. 3, jul./set., 2004 Determination of sun protection factor (SPF) of sunscreens by ultraviolet spectrophotometry Elizângela Abreu Dutra, Daniella Almança Gonçalves da Costa e Oliveira, Erika Rosa Maria Kedor- Hackmann*, Maria Inês Rocha Miritello Santoro Departamento de Farmácia, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo Uniterms: The aim of this research was to determine the sun protection factor • Sunscreens (SPF) of sunscreens emulsions containing chemical and physical • Cosmetic products sunscreens by ultraviolet spectrophotometry. Ten different • Sun protection factor commercially available samples of sunscreen emulsions of various • UV spectrophotometry manufactures were evaluated. The SPF labeled values were in the *Correspondence: range of 8 to 30. The SPF values of the 30% of the analyzed E. R. M. Kedor-Hackmann samples are in close agreement with the labeled SPF, 30% presented Departamento de Farmácia Faculdade de Ciências Farmacêuticas – SPF values above the labeled amount and 40% presented SPF UPS values under the labeled amount. The proposed spectrophotometric Av. Prof. Lineu Prestes, 580 – Bloco 13 – Cidade Universitária method is simple and rapid for the in vitro determination of SPF 05508-900 - São Paulo – SP – Brazil values of sunscreens emulsions. E-mail: [email protected] INTRODUCTION and is responsible for the damage due to sunburn. UVA radiation reaches the deeper layers of the epidermis and The rapid growth of commercially available products dermis and provokes the premature aging of the skin. containing sunscreens indicates that even though a suntan Ultraviolet radiations have been implicated as a causative is still desired, people are conscious of the possible dangers factor of skin cancer.
    [Show full text]
  • Sun Protection
    DRUG NEWS Recommending the Best Sun Protection Clinical Pearls: o Recommend a “broad-spectrum” sunscreen – one that covers UVB, UVA1, and UVA2. o Recommend SPF 30-50 o Advise on non-pharmacological sun protection methods o Emphasize proper sunscreen application technique o Emphasize skin protection when taking drugs known to cause photosensitivity. Familiarize yourself with known implicated drugs by referring to appendix 2. Background 1-4 The sun emits 3 types of ultraviolet (UV) radiation: UVC (100-290 nm), UVB (290-320 nm), and UVA (320 -400 nm). UVA rays can be further divided into the shorter UVA2 rays and the longer UVA1 rays. UVC rays, the shortest rays, are completely absorbed by the ozone layer, whereas UVB rays penetrate the epidermis and UVA rays, the longest rays, penetrate into the dermis. The main consequence of UVB irradiation is sunburn, but can also include immunosuppression and skin cancer. Consequences of UVA radiation include: phototoxicity (i.e. involvement in drug-induced sun sensitivity reactions), photo-aging, immunosuppression, and skin cancer. What is SPF? 2,5,6,7 It is easy to be misled by Sun Protection Factors (SPF). SPF is assessed through a standardized test by finding the ratio of the minimal dose of solar radiation that produces perceptible erythema (i.e., minimal erythema dose) on sunscreen-protected skin compared with unprotected skin. Sunburn is caused primarily by UVB rays (and shorter UVA2 rays), and thus SPF indicates mostly UVB protection. However, UVA protection is equally important since it is responsible for photo-aging and cancer. Therefore, it is important to look for the phrase “broad spectrum” when choosing a sunscreen as broad spectrum indicates both UVB and UVA protection.
    [Show full text]
  • Food and Drug Administration, HHS § 352.20
    Food and Drug Administration, HHS § 352.20 (c) Cinoxate up to 3 percent. than 2 to the finished product. The fin- (d) [Reserved] ished product must have a minimum (e) Dioxybenzone up to 3 percent. SPF of not less than the number of (f) Homosalate up to 15 percent. sunscreen active ingredients used in (g) [Reserved] the combination multiplied by 2. (h) Menthyl anthranilate up to 5 per- (2) Two or more sunscreen active in- cent. gredients identified in § 352.10(b), (c), (i) Octocrylene up to 10 percent. (e), (f), (i) through (l), (o), and (q) may (j) Octyl methoxycinnamate up to 7.5 be combined with each other in a single percent. product when used in the concentra- (k) Octyl salicylate up to 5 percent. tions established for each ingredient in (l) Oxybenzone up to 6 percent. § 352.10. The concentration of each ac- (m) Padimate O up to 8 percent. tive ingredient must be sufficient to (n) Phenylbenzimidazole sulfonic contribute a minimum SPF of not less acid up to 4 percent. than 2 to the finished product. The fin- (o) Sulisobenzone up to 10 percent. ished product must have a minimum (p) Titanium dioxide up to 25 percent. SPF of not less than the number of (q) Trolamine salicylate up to 12 per- sunscreen active ingredients used in cent. the combination multiplied by 2. (r) Zinc oxide up to 25 percent. (b) Combinations of sunscreen and skin [64 FR 27687, May 21, 1999] protectant active ingredients. Any single sunscreen active ingredient or any per- EFFECTIVE DATE NOTE: At 67 FR 41823, June mitted combination of sunscreen ac- 20, 2002, § 352.10 was amended by revising tive ingredients when used in the con- paragraphs (f) through (n), effective Sept.
    [Show full text]
  • Anti-Inflammatory Effects of Sunscreens – Wonder Or Science? by Staton J., Feng H
    technicaltechnical Anti-inflammatory effects of sunscreens – wonder or science? by Staton J., Feng H. Dermatest Pty Ltd Sydney Australia Introduction measured using the mouse ear model, addition. rather than erythema of human skin. The suppression of sun-induced In March 2013, Sayer (5) submitted a Background erythema by addition of anti- Citizens Petition to the FDA, providing Actives used in sunscreens include a inflammatory “excipients” has been a evidence of such activity and proposing number cinnamates, benzophenones controversial issue with the attractiveness the removal of 5 sunscreen actives (from and salicylates (9). Chemicals with of this benefit claim countered by the FDA already depleted list of approved similar structures to these chemical questions of ethics. Some formulators chemicals). families of actives are recognized for of sunscreens have intentionally As none of these reports were based their anaesthetic activities. One active, incorporated ingredients with anti- on experimental design equivalent Trolamine salicylate, is also sold as an inflammatory properties into products to an internationally recognized SPF active in local anaesthetic creams (10). in the belief that this incorporation full panel test protocol (6), we set out Salicylic acid is a non-steroidal anti- will enhance the Sun Protection an experimental schedule in order inflammatory (NSAID). Factor (SPF) and/or act to reduce sun to investigate this potential, based Salicylates such as methyl salicylate induced inflammatory skin responses. on a combination of in vivo SPF and (Oil of Wintergreen) are traditionally Ingredients used with this objective erythemal regression methodology used as a counter irritant for soothing include Ammonium glycyrrhizinate and utilizing a high SPF commercial inflamed skin.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 4.959,205 Brunner Et Al
    United States Patent (19) 11 Patent Number: 4.959,205 Brunner et al. 45 Date of Patent: Sep. 25, 1990 54 COMPOSTION AND METHOD FOR TREATMENT OF DERMAL FOREIGN PATENT DOCUMENTS NFLAMMATION 1539625 6/1976 United Kingdom . OTHER PUBLICATIONS (75) Inventors: Maureen Brunner, San Francisco; Howard Palefsky, Atherton, both of The Merck Index, 1976, 9th edition, pp. 629 and 630. Calif. B. Ljunggren et al, Arch Derm Forsch (1973)248:1-12. J. P. Callen et al, Arthritis Rheum (Aug. 1988) 31:1007-13. (73) Assignee: Collagen Corporation, Palo Alto, L. H. Kligman, J Invest Dermatol (1987) 88:12s-17s. Calif. A. D. Pearse et al, J Invest Dermatol (1987) 88:83-87. M. Pathak, Dermatologic Clin (1986) 4:321-34 (Pathak 21 Appl. No.: 327,488 I). M. Pathak et al, J Amer Acad Dernatol (1986) 22 Filed: Mar. 23, 1989 15:894-99, T. Schwartz et al, Dermatologica (1985) 171:450-58. (51) Int. Cl. ......................... A61K 7/40; A61K 7/42; L. E. Gibson et al, Geriatrics (1985) 40:87-92. A61K 31/56 K. Kyuki et al, JapJ Pharmacol (1983) 33:121-32. (52) U.S. C. ...................................... 424/59; 514/177; M. Pathak, JAmer Acad Dermatol (1982) 7:285-312. 514/847; 514/886; 514/887; 514/938 P. Peters et al, Agents & Actions (1977) 7:545-53. 58) Field of Search........................... 424/59; 514/887 Primary Examiner-Dale R. Ore Attorney, Agent, or Firm-Irel & Manella 56) References Cited (57) ABSTRACT U.S. PATENT DOCUMENTS Mild dermal inflammation, such as mild eczema and 4,083,974 4/1978 Turi......................................
    [Show full text]
  • Foolproof Tips for Staying Safe in The
    Summer Sun eFoolproofssentials Tips for Staying Safe in the Sun Happy summer! It’s finally summer! That means cookouts, beach vacations, and relaxing by the pool. Not many people will argue that there’s a better way to celebrate the summer season than by spending more time outdoors and enjoying some sunshine. However, with the summer season comes some responsibility to take care of yourself – especially your skin. Too much time in the sun can lead to wrinkles, premature aging, and even skin cancer. While sunburns might not seem like a big deal, they can do a lot of damage in a short amount of time. On average, about half of the U.S. population experiences a sunburn at least once a year. This means that many Americans aren’t practicing essential sun safety rules. Skin cancer is the most common form of cancer in the United States. It’s estimated that nearly 9,500 people in the U.S. are diagnosed with it every day, according to the American Academy of Dermatology. And according to the Skin Cancer Foundation, one in five Americans will develop skin cancer by the age of 70. These statistics show that many Americans aren’t doing enough to protect their skin and their overall health. We created this sun safety guide to educate you about the importance of sun protection, as well as share some tips on how to have a safe summer. In this guide you’ll learn: • Best practices for sun safety • How to choose the best sunscreen • Common risk factors for skin cancer • Tips for skin cancer prevention Plus, we also included a printable tip sheet for employers to pass around the office to help educate their employees on the importance of sun safety.
    [Show full text]